Fulcrum Therapeutics to Participate in Upcoming May Conferences

Core Viewpoint - Fulcrum Therapeutics, Inc. is actively participating in upcoming conferences to engage with investors and stakeholders, highlighting its focus on developing treatments for genetically defined rare diseases [1][3]. Company Overview - Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing small molecules aimed at improving the lives of patients with genetically defined rare diseases, particularly in areas with high unmet medical needs [2]. - The company's lead clinical program is pociredir, a small molecule designed to enhance fetal hemoglobin expression for treating sickle cell disease (SCD) [2]. - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression, addressing the root causes of gene mis-expression [2]. Upcoming Events - The company will participate in the H.C. Wainwright BioConnect Investor Conference on May 20, 2025, in New York, New York [3]. - Fulcrum will also take part in the RBC Capital Markets Global Healthcare Conference on May 21, 2025, with a fireside chat scheduled for 3:35 pm ET [3].